Bengaluru-based pharmaceutical major Strides Shasun Limited on Tuesday announced that the company has received approval from the US Food and Drug Administration (USFDA) to market Potassium Citrate tablets, which is used for preventing certain types of kidney stones.
The pharma company, which recently acquired the Australian operations of US-based Amneal Pharma, will launch the Potassium Citrate extended-release tablets, immediately, the company said.
The market for Potassium Citrate in the US is approximately $110 million, according to the data provided by global information, services and technology firm IMS Health.
Potassium Citrate extended release tablet works by neutrilising some of the acid in the urine, thus helping reduce the formation of crystals.
Strides Shasun will be the second generic player to commercialise the product for the US market.